

## OBSTETRICS

# Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State



Erica M. Lokken, PhD, MS; Emily M. Huebner, MS; G. Gray Taylor, BA; Sarah Hendrickson, MD; Jeroen Vanderhoeven, MD; Alisa Kachikis, MD, MS; Brahm Coler, BA; Christie L. Walker, MD, MPH; Jessica S. Sheng, MD; Benjamin J. S. al-Haddad, MD, PhD; Stephen A. McCartney, MD, PhD; Nicole M. Kretzer, MD, PhD; Rebecca Resnick, PhD; Nena Barnhart, MD; Vera Schulte, BA; Brittany Bergam, BS; Kimberly K. Ma, MD; Catherine Albright, MD, MS; Valerie Larios; Lori Kelley, MSN, RN; Victoria Larios, BSN, RN; Sharilyn Emhoff, BSN, RN; Jasmine Rah, BA; Kristin Retzlaff, RN; Chad Thomas, MD, PhD; Bettina W. Paek, MD; Rita J. Hsu, MD, MS; Anne Erickson, MD; Andrew Chang, BS; Timothy Mitchell, MD; Joseph K. Hwang, MD; Stephen Erickson, MD; Shani Delaney, MD; Karen Archabald, MD; Carolyn R. Kline, MD, MPH; Sylvia M. LaCourse, MD, MPH; Kristina M. Adams Waldorf, MD;  
On behalf of the Washington State COVID-19 in Pregnancy Collaborative

**BACKGROUND:** Evidence is accumulating that coronavirus disease 2019 increases the risk of hospitalization and mechanical ventilation in pregnant patients and for preterm delivery. However, the impact on maternal mortality and whether morbidity is differentially affected by disease severity at delivery and trimester of infection are unknown.

**OBJECTIVE:** This study aimed to describe disease severity and outcomes of severe acute respiratory syndrome coronavirus 2 infections in pregnancy across the Washington State, including pregnancy complications and outcomes, hospitalization, and case fatality.

**STUDY DESIGN:** Pregnant patients with a polymerase chain reaction—confirmed severe acute respiratory syndrome coronavirus 2 infection between March 1, 2020, and June 30, 2020, were identified in a multicenter retrospective cohort study from 35 sites in Washington State. Sites captured 61% of annual state deliveries. Case-fatality rates in pregnancy were compared with coronavirus disease 2019 fatality rates in similarly aged adults in Washington State using rate ratios and rate differences. Maternal and neonatal outcomes were compared by trimester of infection and disease severity at the time of delivery.

**RESULTS:** The principal study findings were as follows: (1) among 240 pregnant patients in Washington State with severe acute respiratory syndrome coronavirus 2 infections, 1 in 11 developed severe or critical disease, 1 in 10 were hospitalized for coronavirus disease 2019, and 1 in 80 died; (2) the coronavirus disease 2019—associated hospitalization rate was 3.5-fold higher than in similarly aged adults in Washington State

(10.0% vs 2.8%; rate ratio, 3.5; 95% confidence interval, 2.3–5.3); (3) pregnant patients hospitalized for a respiratory concern were more likely to have a comorbidity or underlying conditions including asthma, hypertension, type 2 diabetes mellitus, autoimmune disease, and class III obesity; (4) 3 maternal deaths (1.3%) were attributed to coronavirus disease 2019 for a maternal mortality rate of 1250 of 100,000 pregnancies (95% confidence interval, 257–3653); (5) the coronavirus disease 2019 case fatality in pregnancy was a significant 13.6-fold (95% confidence interval, 2.7–43.6) higher in pregnant patients than in similarly aged individuals in Washington State with an absolute difference in mortality rate of 1.2% (95% confidence interval, –0.3 to 2.6); and (6) preterm birth was significantly higher among women with severe or critical coronavirus disease 2019 at delivery than for women who had recovered from coronavirus disease 2019 (45.4% severe or critical coronavirus disease 2019 vs 5.2% mild coronavirus disease 2019;  $P < .001$ ).

**CONCLUSION:** Coronavirus disease 2019 hospitalization and case-fatality rates in pregnant patients were significantly higher than in similarly aged adults in Washington State. These data indicate that pregnant patients are at risk of severe or critical disease and mortality compared to nonpregnant adults, and also at risk for preterm birth.

**Key words:** case fatality, coronavirus, COVID-19, fetus, maternal mortality, pneumonia, pregnancy, preterm birth, SARS-CoV-2

**Cite this article as:** Lokken EM, Huebner EM, Taylor GG, et al. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. *Am J Obstet Gynecol* 2021;225:77.e1-14.

0002-9378/\$36.00

© 2021 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.ajog.2020.12.1221>

Click [Video](#) under article title in Contents at [ajog.org](#)

## Introduction

In the early months of the coronavirus disease 2019 (COVID-19) pandemic, pregnant patients faced uncertain risks associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<sup>1</sup> SARS-CoV-2 infection in pregnancy is now known to result in a spectrum of asymptomatic to critical maternal disease.<sup>2–7</sup> Evidence is accumulating that pregnant patients with

SARS-CoV-2 infections are at a higher risk of hospitalization, mechanical ventilation, intensive care unit (ICU) admission, and preterm birth.<sup>2,7–11</sup> In June of 2020, a United States population-based study by the Centers for Disease Control and Prevention (CDC) found that pregnant patients with SARS-CoV-2 infections were at a higher risk of hospitalization, mechanical ventilation, and ICU admission, but mortality rates were

## AJOG at a Glance

**Why was this study conducted?**

Whether coronavirus disease 2019 (COVID-19) poses a risk for pregnant women to develop severe or critical disease and the impact on maternal mortality and morbidity are poorly understood.

**Key findings**

In a multicenter retrospective cohort study of facilities covering 61% of annual births in Washington State, there were 240 pregnant patients with severe acute respiratory syndrome coronavirus 2 infections, 24 COVID-19–associated hospitalizations (10%), and 3 maternal deaths (1.25%). The COVID-19 case-fatality rate in pregnant patients was 13.6-fold higher than similarly aged individuals with COVID-19.

**What does this add to what is known?**

Our data suggest the impact of COVID-19 on pregnant patients is greater than currently appreciated, with an elevated risk of maternal death.

similar between pregnant and nonpregnant reproductive-aged women (0.2%).<sup>8</sup> A subsequent CDC study including more cases and restricted to symptomatic cases in pregnancy found an increased risk of mortality among pregnant women vs nonpregnant women with SARS-CoV-2,<sup>12</sup> leading the CDC to revise public health guidance to indicate that pregnant women are at risk of severe COVID-19 disease.<sup>9</sup> However, because pregnancy status was missing or unknown in up to three-quarters of COVID-19 cases reported to the United States CDC, these results may be biased and the extent to which pregnant women experience severe or critical disease with an increased risk of mortality needs further evaluation.<sup>8,10</sup>

Additional population-based studies of COVID-19 in pregnancy including fatality rates in pregnancy would help determine the extent to which pregnant patients with COVID-19 are at risk of severe or critical disease similar to the 2009 H1N1 influenza pandemic.<sup>13–15</sup> Inclusion of all pregnant patients with SARS-CoV-2 including milder and asymptomatic cases managed as outpatients is critical for determining the impact of COVID-19 on pregnancy outcomes and the possibility of severe or critical maternal disease. Furthermore, whether the timing of SARS-CoV-2 infection (eg, trimester of infection, status at time of delivery) is

associated with adverse pregnancy outcomes, such as hypertensive disease in pregnancy or preterm birth, has not been thoroughly interrogated. We established the Washington State COVID-19 in Pregnancy Collaborative (WA-CPC) as a multicenter retrospective cohort study to capture COVID-19 cases in pregnancy.<sup>2</sup> The WA-CPC network captures the majority of annual deliveries in the state, gathers clinical data on COVID-19 outcomes in pregnancy, and shares information and strategies to improve patient care. The objective of this study was to describe disease severity and outcomes of COVID-19 in pregnancy across Washington State including pregnancy complications and outcomes, hospitalization, and case fatality.

**Methods****Washington State COVID-19 in Pregnancy Collaborative**

The WA-CPC includes 35 large hospitals (n=22) and clinic systems providing prenatal care (n=13) in Washington State, encompassing 61% of the approximate 86,000 annual state deliveries (Supplemental Table).<sup>16</sup> The majority of the participating hospitals had instituted universal screening for SARS-CoV-2 by nasopharyngeal swab before or at the time of the delivery admission by May 2020 (March, 14%; April, 64%; May, 76%), with the

remaining hospitals initiating universal testing for scheduled delivery admissions only.

Eligible cases were pregnant patients ( $\geq 18$  years old) with a polymerase chain reaction (PCR) test–confirmed SARS-CoV-2 infection during any trimester of pregnancy detected between March 1, 2020, and June 30, 2020.<sup>16</sup> Pregnant women were tested for many reasons including exposure to a known SARS-CoV-2 case, symptoms, recent travel, personal requests, and universal screening at labor and delivery. Collaborating sites identified eligible patients using diagnostic codes and site-specific algorithms. Deidentified data were abstracted from electronic medical records, and each record was reviewed by a second abstractor for quality control.<sup>2</sup> Final disease and delivery outcome data were abstracted between July 7, 2020, and September 10, 2020, based on site capacity. COVID-19 disease severity was defined as<sup>1</sup> (1) mild (asymptomatic, nonpneumonia, mild pneumonia), (2) severe (dyspnea, respiratory rate of  $\geq 30$  breaths per minute, percutaneous oxygen saturation of  $\geq 93\%$  on room air at rest, arterial oxygen tension over inspiratory oxygen fraction of  $< 300$  mm Hg, or lung infiltrates of  $> 50\%$  within 24–48 hours), and (3) critical (severe respiratory distress, respiratory failure requiring mechanical ventilation, shock, or multiple organ dysfunction or failure).<sup>17,18</sup> Hospitalized participants were considered “hospitalized owing to COVID-19 concern” based on the reason for admission noted by the abstracting team, including respiratory concerns and “other” COVID-19 concerns. Patients admitted for concurrent obstetrical (eg, delivery) and COVID-19 concerns were considered hospitalized for COVID-19 concern.

This multisite medical records review was approved by institutional review boards (IRBs) at the University of Washington (STUDY# 00009701, approved March 6, 2020) and Swedish Medical Center (STUDY #2020000172, approved March 19, 2020). All other sites entered into reliance agreements with the University of Washington IRB.

## Statistical analyses

Demographic and SARS-CoV-2 infection characteristics in pregnancy were summarized by proportions and medians (interquartile range [IQR]) overall and were compared across COVID-19 hospitalization status using chi-squared and Kruskal-Wallis tests. Maternal, delivery, and neonatal outcome characteristics were summarized for patients who had delivered by the time of final chart abstraction. These characteristics were described overall, by trimester of infection, and by the patient's COVID-19 status at the time of delivery. Pregnant patients were categorized as "COVID-19 recovered" if they were SARS-CoV-2 negative at the time of delivery or their last positive test was >14 days before delivery in alignment with quarantine guidelines during the study period; this categorization was independent of disease severity. Women who were PCR positive for SARS-CoV-2 in the preceding 14 days of delivery or admitted with post-COVID-19 complications at the time of delivery (even in absence of continued PCR positivity) were considered to have "active COVID-19" and further classified by mild or severe or critical disease status. Delivery outcomes were compared among COVID-19 recovered, mild COVID-19, and severe or critical COVID at delivery and by trimester of infection, using the chi-squared and Kruskal-Wallis tests, where appropriate.

Collaborating sites captured the majority of pregnancies in Washington State with the highest coverage in regions most affected by COVID-19 (Supplemental Table).<sup>19</sup> We calculated crude rate ratios (RRs) and rate differences (RDs) with Poisson exact 95% confidence interval (CI) to compare COVID-19-associated hospitalization and case-fatality rates in our study population with rates experienced by 20- to 39-year-old adults with SARS-CoV-2 in Washington State using publicly available data from the Washington State Department of Health; this comparison group served as the best publicly available proxy for rates in reproductive-aged women because data were only available

by age group or gender, but not both.<sup>19</sup> Notably, nonpregnant adults were tested for SARS-CoV-2 for the same reasons as pregnant people including universal screening before medical procedures. Hospitalization and case-fatality rates at the state level were estimated between March 1, 2020, and September 26, 2020, because outcomes were collected for some study participants through September and to account for the lag between infection detection and mortality outcomes. Both crude RR and RD were calculated given the small number of events in this study population to ascertain both relative and absolute risks.

## Results

### Severe acute respiratory syndrome coronavirus 2 infections in pregnancy

A total of 240 confirmed cases of SARS-CoV-2 infections in pregnancy were detected by WA-CPC sites including 24 (10.0%) who were hospitalized for a COVID-19 respiratory concern. Demographic and coexisting conditions are presented in Table 1. Of these, 46 cases were previously published including details on 8 deliveries.<sup>2</sup> The median age was 28 years (IQR, 24–33.5). Nearly half were white (113 of 240) and half reported Hispanic ethnicity (126 of 240). Two-thirds were publicly insured (160 of 240). The most common underlying conditions were prepregnancy obesity (body mass index of  $\geq 30.0$ , 45.3% [102 of 225]), asthma (8.3%; 20 of 240), type 2 diabetes mellitus (5.4%; 13 of 240), and hypertension (4.6%; 11 of 240). Pregnant patients with SARS-CoV-2 infections who were hospitalized for a COVID-19 concern were slightly older (median, 32 vs 28 years old;  $P=.04$ ) and more likely than nonhospitalized pregnant patients with SARS-CoV-2 infection to have at least 1 comorbidity or underlying condition (45.8% vs 17.6%;  $P=.001$ ), such as asthma (20.8% vs 6.9%;  $P=.02$ ), hypertension (20.8% vs 2.8%;  $P<.001$ ), type 2 diabetes mellitus (12.5% vs 4.6%;  $P=.11$ ), autoimmune disease (8.3% vs 0.9%;  $P<.01$ ), and class III obesity (21.1% vs 6.3%;  $P=.01$ ) (Table 1).

Approximately half of the SARS-CoV-2 cases were detected in the third trimester (56.3%; 135 of 240), with 27.9% (67 of 240) in the second trimester and 15.8% (38 of 240) in the first trimester (Table 2). At the time of the first positive COVID-19 test, 77.1% of pregnant patients (185 of 240) were symptomatic (or reported resolved COVID-19 symptoms) with the remaining being asymptomatic (22.9%; 55 of 240). Mild COVID-19 disease occurred in 90.8% (158 of 240, including 55 asymptomatic cases), with severe and critical disease occurring in 7.5% (18 of 240) and 1.7% (4 of 240), respectively. Notably, 3 maternal deaths owing to COVID-19 complications occurred (1.3%; 3 of 240).

### Pregnant patients hospitalized for coronavirus disease 2019—associated respiratory concern

Notably, 24 cases (10.0%) were hospitalized specifically for COVID-19 symptoms, with 3 having concurrent delivery-related indications (Table 3). One-third of the hospitalized patients (8 of 24) were admitted to the ICU (3.3% of study population; 8 of 240); 1 pregnant patient was hospitalized and admitted to the ICU twice. Overall, the SARS-CoV-2 hospitalization rate in pregnant patients was 3.5-fold higher than the rate among individuals aged 20 to 39 years with confirmed SARS-CoV-2 in Washington State (10.0% [24 of 240] vs 2.8% [985 of 34,902]; RR, 3.5; 95% CI, 2.3–5.3) (Table 4).

Most pregnant patients hospitalized for COVID-19 had severe or critical disease (79.2%; 19 of 24), but 20.8% (5 of 24) who were admitted for a COVID-19 concern were ultimately considered to have mild disease by the disease severity criteria (Table 2).<sup>17,18</sup> All 4 pregnant patients with critical COVID-19 disease developed confirmed or suspected acute respiratory distress syndrome; 3 of these patients ultimately died. Almost half of the hospitalized patients (40.9%; 9 of 22) delivered during their admission for COVID-19 (Table 3); 19 of the hospitalized patients (79.1%; 19 of 24) received some level of oxygen support,

**TABLE 1**  
**Demographics and comorbidities by hospitalization status in pregnant patients with SARS-CoV-2 infection**

Characteristics	All pregnant patients (N=240) <sup>a</sup>	Not hospitalized for COVID-19 concern (n=216)	Hospitalized for COVID-19 concern (n=24)	P value
<b>Demographics</b>				
Age (y)	28 (24–34)	28 (24–33)	32 (26–35)	.04
Race				.14
American Indian or Alaska Native	10 (4.2)	8 (3.7)	2 (8.3)	
Asian	8 (3.3)	8 (3.7)	0 (0)	
Native Hawaiian or other Pacific Islander	8 (3.3)	5 (2.3)	3 (12.5)	
Black or African American	20 (8.3)	19 (8.8)	1 (4.2)	
White	113 (47.1)	104 (48.2)	9 (37.5)	
Multiracial	2 (0.8)	2 (0.9)	0 (0)	
Other	28 (11.7)	26 (12.0)	2 (8.3)	
Unknown	51 (21.3)	44 (20.4)	7 (29.2)	
Ethnicity				.29
Hispanic or Latino	126 (52.5)	117 (54.2)	9 (37.5)	
Not Hispanic or Latino	108 (45.0)	94 (43.5)	14 (58.3)	
Unknown	6 (2.5)	5 (2.3)	1 (4.2)	
Type of insurance at diagnosis				.11
Public	160 (66.7)	146 (67.6)	14 (58.3)	
Private	74 (30.8)	66 (30.6)	8 (33.3)	
Other	4 (1.7)	2 (0.9)	2 (8.3)	
Uninsured	1 (0.4)	1 (0.5)	0 (0)	
Unknown	1 (0.4)	1 (0.5)	0 (0)	
<b>Pregnancy history<sup>b</sup></b>				
Parity	1 (1–3)	1 (1–2)	1.5 (1–4)	.08
History of preterm birth	23 (9.6)	21 (9.8)	2 (8.3)	.82
<b>Prepregnancy comorbidities or underlying conditions</b>				
Any comorbidity or underlying condition (excluding obesity) <sup>c</sup>	49 (20.4)	38 (17.6)	11 (45.8)	.001
Asthma	20 (8.3)	15 (6.9)	5 (20.8)	.02
Type 2 diabetes mellitus	13 (5.4)	10 (4.6)	3 (12.5)	.11
Hypertension	11 (4.6)	6 (2.8)	5 (20.8)	<.001
Cardiovascular disease	6 (2.5)	5 (2.3)	1 (4.2)	.58
Autoimmune disease	4 (1.7)	2 (0.9)	2 (8.3)	<.01
Hypothyroidism	4 (1.7)	3 (1.4)	1 (4.2)	.31

Lokken et al. COVID-19 disease and mortality in pregnancy. Am J Obstet Gynecol 2021.

(continued)

with 16.7% of hospitalized patients (4 of 24) receiving mechanical ventilation. Laboratory testing in addition to a SARS-CoV-2 PCR was performed on a minority of patients, who typically had

severe or critical COVID-19. Using pregnancy-specific norms for laboratory values,<sup>20</sup> 43.5% (10 of 23) had lymphopenia, 77.3% (17 of 22) had an elevated aspartate aminotransferase, 53.3% (8 of

15) had an elevated C-reactive protein, 29.4% (5 of 17) had an elevated D-dimer, and 4.4% (1 of 23) had an elevated creatinine during COVID-19-associated hospitalization (Table 3). The

**TABLE 1**  
**Demographics and comorbidities by hospitalization status in pregnant patients with SARS-CoV-2 infection** (continued)

Characteristics	All pregnant patients (N=240) <sup>a</sup>	Not hospitalized for COVID-19 concern (n=216)	Hospitalized for COVID-19 concern (n=24)	P value
Prepregnancy BMI (kg/m <sup>2</sup> ) <sup>d</sup>				.02
Underweight (<18.5)	3 (1.3)	3 (1.5)	0 (0)	
Normal (18.5–24.9)	57 (25.3)	55 (26.7)	2 (10.5)	
Overweight (25.0–29.9)	63 (28.0)	56 (27.2)	7 (36.8)	
Obese (≥30.0)	102 (45.3)	92 (44.7)	10 (52.6)	
Class 3 obesity (BMI of ≥40 kg/m <sup>2</sup> ) <sup>d</sup>	17 (7.6)	13 (6.3)	4 (21.1)	.02

BMI, body mass index; COVID-19, coronavirus disease 2019; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Summarized as number (percentage) or median (IQR); <sup>b</sup> Parity and history of preterm birth missing for 1 participant; <sup>c</sup> Comorbidities assessed for the data collection tool included diabetes mellitus, asthma, reactive airway disease, hypertension, hypothyroidism, cardiovascular disease, autoimmune disease, HIV, immunosuppressive medication use, cirrhosis, hepatitis A history, hepatitis C antibody, previous or current cancer, tuberculosis, prepregnancy kidney disease, chronic obstructive pulmonary disease, seizure disorder, and cerebrovascular disease; <sup>d</sup> Data only available for 225 patients. Prepregnancy weight or weight before 12 weeks' gestational age was used if prepregnancy weight was not available. For 1 patient, their weight at 14 weeks' gestation was used to calculate prepregnancy BMI.

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

most common targeted treatments for COVID-19 disease among hospitalized pregnant patients were remdesivir (37.5%; 9 of 24), followed by dexamethasone (12.5%; 3 of 24), hydroxychloroquine (8.3%; 2 of 24), and convalescent plasma (8.3%; 2 of 24) with some patients receiving multiple therapies.

### Maternal deaths in pregnant patients with severe acute respiratory syndrome coronavirus 2019 infection

There were 3 deaths among 240 pregnant patients with a SARS-CoV-2 infection for a maternal mortality rate of 1250 of 100,000 pregnancies (95% CI, 258–3653) (Table 4). Overall, the SARS-CoV-2 case-fatality rate among included pregnant patients was a significant 13.6-fold higher in pregnant patients than the 91.7 of 100,000 rate in similarly aged 20- to 39-year-olds in Washington State (RR, 13.6; 95% CI, 2.7–43.6), equating to an absolute RD of 1.2% (95% CI, –0.26 to 2.57) (Table 4). The 3 deaths in pregnant patients constitute 9.4% of the total deaths (3 of 32) in this age group in Washington State assuming all 3 deaths were included in the state's surveillance data.

The 3 pregnant patients who died owing to COVID-19 disease were all

publicly insured, aged 35 to 39 years, and from minority racial-ethnic groups. Each had significant comorbidities that included obesity, hypertension, autoimmune disease, or congenital heart disease. Notably, 2 of the maternal deaths occurred during the early postpartum period and 1 in the first trimester; 1 patient died from respiratory failure before she could have benefited from COVID-19 therapeutics. One died from a postpartum pulmonary embolus after recovering from a prolonged COVID-19 hospitalization where she received venous thromboprophylaxis during and after her hospital stay. A third patient died of respiratory failure after a prolonged ICU stay despite multiple COVID-19 therapeutics. One of the 2 neonates born to women, who died postpartum, was healthy. The other neonate was preterm and admitted to the neonatal ICU (NICU) for respiratory distress; SARS-CoV-2 testing data were missing for this neonate.

### Maternal and pregnancy outcomes by trimester of infection and severity of severe acute respiratory syndrome coronavirus 2 infection

The final pregnancy outcome data were available for 65.8% of pregnant patients (158 of 240) with a SARS-CoV-2 infection, including 7.9% (3 of 38) patients

with infection in the first trimester, 40.3% (27 of 67) in the second trimester, and 94.8% (128 of 136) in the third trimester (Table 2). For the 3 patients with pregnancy outcome data associated with a SARS-CoV-2 infection in the first trimester, there was 1 maternal death and 2 spontaneous abortions. For the remaining 155 patients with infections in the second and third trimesters, nearly all patients had a live birth (98.7%; n=153) (Table 5). There were 2 stillbirths in this study; neither stillbirth was attributed to SARS-CoV-2 infection. An extensive investigation to determine the cause of death was performed in 1 case, as previously reported, and a genetic cause was attributed to the second death.<sup>2</sup> Maternal and delivery characteristics were similar between women with SARS-CoV-2 infections in the second and third trimesters (Table 5).

At the time of delivery for pregnant patients with second- and third-trimester SARS-CoV-2 infections, 43.2% (67 of 155) were considered recovered from COVID-19 (including 11 women experiencing severe disease earlier in pregnancy); an additional 49.7% (77 of 155) had mild COVID-19, and 7.1% (11 of 155) had severe or critical COVID-19 at delivery (Table 6). Pregnant women with severe or critical COVID-19 at delivery were more likely to have a preterm birth (45.4% severe or

**TABLE 2**  
**COVID-19 severity, hospitalization, and outcomes by trimester of infection in pregnant patients**

Characteristic	All pregnant patients N=240 <sup>a</sup>	Hospitalization status		Pvalue	Trimester of SARS-CoV-2 infection			Pvalue
		Not hospitalized for COVID-19 concern (n=216)	Hospitalized for COVID-19 concern (n=24) <sup>b</sup>		First (n=38)	Second (n=67)	Third (n=135)	
Trimester of infection <sup>c</sup>				<.001				
First	38 (15.8)	37 (17.1)	1 (4.2)					
Second	67 (27.9)	62 (28.7)	5 (20.8)					
Third	135 (56.3)	117 (54.2)	18 (75.0)					
Symptomatic at first COVID-19 positive test <sup>c</sup>				.02				<.001
Asymptomatic	55 (22.9)	54 (25.0)	1 <sup>d</sup> (4.2)		3 (7.9)	3 (4.5)	49 (36.3)	
Symptomatic	185 (77.1)	162 (75.0)	23 (95.8)		35 (92.1)	64 (95.5)	86 (63.7)	
Disease severity				<.001				.28
Mild	218 (90.8)	213 (98.6)	5 (20.8)		37 (97.4)	62 (92.5)	119 (88.2)	
Severe	18 (7.5)	3 <sup>e</sup> (1.4)	15 (62.5)		0 (0)	4 (6.0)	14 (10.4)	
Critical	4 (1.7)	0 (0)	4 (16.7)		1 (2.6)	1 (1.5)	2 (1.5)	
Outcomes								
Hospitalized for COVID-19 concern	24 (10.0)				1 (2.6)	5 (7.5)	18 (13.3)	.11
Admitted to ICU	8 (3.3)	0 (0.0)	8 (33.3)		0 (0)	1 (1.5)	7 (5.2)	.74
Maternal death	3 (1.3)	0 (0.0)	3 (12.5)	<.001	1 (2.6)	1 (1.5)	1 (0.7)	.64
Final pregnancy outcome <sup>f</sup>	158 (65.8)	135 (62.5)	23 (95.8)	.001	3 (7.9)	27 (40.3)	128 (94.8)	<.001
COVID-19 at final outcome <sup>g</sup>	90 (57.0)	78 (57.8)	12 (52.1)	.62	2 (66.7)	2 (7.4)	86 (67.2)	<.001
Recovered from COVID-19 at final outcome	68 (43.0)	57 (42.2)	11 (47.8)	.62	1 (33.3)	25 (92.6)	42 (32.8)	<.001

Gray shading indicates cells with no data.

COVID-19, coronavirus disease 2019; ICU, intensive care unit; SARS-COV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Summarized as number (percentage) or median (interquartile range); <sup>b</sup> One patient was hospitalized and admitted to ICU twice several months apart; <sup>c</sup> At the time of the first positive SARS-CoV-2 test; <sup>d</sup> This patient was tested owing to a known exposure to COVID-19 and became symptomatic before hospitalization; <sup>e</sup> All 3 patients had dyspnea but were not ultimately hospitalized; <sup>f</sup> Includes 1 maternal death and 2 spontaneous abortions in pregnant patients with first-trimester SARS-CoV-2 infections; <sup>g</sup> Includes pregnant patients with mild or severe or critical COVID-19 at the time of final pregnancy outcome.

Lokken et al. COVID-19 disease and mortality in pregnancy. Am J Obstet Gynecol 2021.

critical COVID-19 vs 5.2% mild COVID-19 vs 9.0% recovered;  $P<.001$ ) and to deliver owing to COVID-19 (63.6% severe or critical COVID-19 vs 2.6% mild COVID-19 vs 0% recovered;  $P<.001$ ). The frequency of gestational diabetes mellitus and new-onset hypertensive disorders of pregnancy or postpartum, was similar by COVID-19 status at delivery (Table 6).

### Neonatal outcomes

There were 3 sets of twins for a total of 156 live-born neonates. Neonates born to mothers with severe or critical COVID-19 at the time of delivery were more likely to have low birthweight (<2500 g) and more likely to be admitted to the NICU for fetal indications than those born to women with mild COVID-19 or recovered from COVID-19 at the time of delivery (Table 6). Of the 144 neonates with SARS-CoV-2 test results available, one-third were tested at least once (31.3%; 45 of 144) and none tested positive (Table 5). The remaining two-thirds were not tested for SARS-CoV-2. Neonatal testing was most common among pregnant patients with severe COVID-19 at delivery (77.9%; 7 of 9) but conducted in only half of patients with mild COVID-19 at delivery (44.9%; 35 of 77); SARS-CoV-2 testing was uncommon among women considered COVID-19 recovered at delivery (5.3%; 3 of 57). Neonates were generally healthy with the most common diagnoses of respiratory distress ( $n=6$ ), hyperbilirubinemia ( $n=4$ ), and possible sepsis ( $n=3$ ). Other diagnoses included meconium aspiration syndrome, metabolic acidosis, hypoglycemia, supraventricular tachycardia, pneumothorax, and hypotonia.

## Discussion

### Principal findings

Although most pregnant patients with SARS-CoV-2 in pregnancy experienced mild disease and recovered, 1 in 11 developed severe or critical disease, 1 in 10 were hospitalized specifically for a COVID-19 concern, 1 in 30 were admitted to the ICU for respiratory concerns, 1 in 60 were mechanically

**TABLE 3**  
Disease severity and COVID-19 therapies used in 24 pregnant patients hospitalized for COVID-19 concern

Characteristic	Hospitalized owing to COVID-19 concern (n=24) <sup>a</sup>	
	n	n (%) or median (IQR)
Gestational age at admission (wk) <sup>b</sup>	23	32.4 (26–36.1)
Admitted for COVID-19 concern and delivery indication	24	3 (12.5)
Delivered while admitted for COVID-19 concern <sup>c</sup>	22	9 (40.9)
Admitted to ICU	24	8 (33.3)
Highest level of oxygen support	24	
None		5 (20.8)
Nasal cannula		8 (33.3)
High-flow nasal cannula		3 (12.5)
Nonrebreather mask		4 (16.7)
Mechanical ventilation		4 (16.7)
COVID-19 therapies <sup>d</sup>	24	
None		7 (29.1)
Remdesivir		9 (37.5)
Hydroxychloroquine		2 (8.3)
Convalescent plasma		2 (8.3)
Dexamethasone		3 (12.5)
Vasopressor support	24	4 (16.7)
Laboratory measures <sup>e</sup>		n (%) or median (range)
Lowest white blood cell count ( $10^3$ per $\mu\text{L}$ blood)	23	6.1 (2.8–19)
Lymphopenia ( $\leq 5.6 \times 10^3$ per $\mu\text{L}$ blood)	23	10 (43.5)
Highest aspartate aminotransferase (units/L)	22	46 (12–377)
Elevated AST ( $\geq 33$ units/L)	22	17 (77.3)
Highest D-dimer ( $\mu\text{g/mL}$ )	17	1.5 (0.2–4.5)
Elevated D-dimer ( $>3.3$ $\mu\text{g/L}$ )	17	5 (29.4)
Highest C-reactive protein (mg/L)	15	25.7 (1.6–281.1)
Elevated C-reactive protein ( $\geq 22.3$ mg/L)	15	8 (53.3)
Highest creatinine (mg/dL)	23	0.7 (0.4–1.2)
Elevated creatinine ( $>0.9$ mg/dL)	23	1 (4.4)

COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Number (percentage) or median (IQR). One patient was hospitalized twice several months apart; clinical details are reported for the first hospitalization only during acute COVID-19 infection. An additional patient diagnosed as having SARS-CoV-2 at delivery was subsequently readmitted for COVID-19 concern after delivery; <sup>b</sup>  $n=23$ , excluding 1 patient who was admitted after delivery; <sup>c</sup>  $n=22$ , excluding 1 patient who was admitted after delivery and 1 first-trimester maternal death; <sup>d</sup> Patients receiving multiple targeted COVID-19 therapies are included in each relevant category; <sup>e</sup> Laboratory values represented the highest or lowest detected during hospitalization; for some patients, this was after delivery. Thresholds for abnormal laboratory values were specific to pregnancy.<sup>21</sup>

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

ventilated, and 1 in 80 died. Case-fatality rates in pregnant patients with SARS-CoV-2 infections were nearly 14-fold higher than that of similarly aged individuals in Washington State with COVID-19, making up nearly 10% of

TABLE 4

**SARS-CoV-2 hospitalizations and case-fatality rates among pregnant women in Washington State: comparisons with Washington State data COVID-19 surveillance data**

Population	n	N	Rate	RR	RD
<b>COVID-19 hospitalization</b>					
			%	(95% CI)	RR (95% CI) RD % (95% CI)
WA-CPC: pregnant patients with SARS-CoV-2	24	240	10.0	(6.4–14.9)	3.5 (2.3–5.3) 7.2 (3.2–11.2)
Washington State: 20- to 39-y-olds with SARS-CoV-2	985	34,902	2.8	(2.6–3.0)	Ref Ref
<b>COVID-19 deaths</b>					
			Deaths/100,000	(95% CI)	RR (95% CI) Deaths/100,000 (95% CI)
WA-CPC: pregnant patients with SARS-CoV-2	3	240	1250.0	(257.8–3653.0)	13.6 (2.7–43.6) 1158.3 (–256.5 to 2573.2)
Washington State: 20- to 39-y-olds with SARS-CoV-2	32	34,902	91.7	(62.7–129.4)	Ref Ref

Publicly available COVID-19 hospitalization and mortality data for 20- to 39-year-olds in Washington State were obtained from the WA-CPC surveillance dashboard.<sup>19</sup> The RR compares the SARS-CoV-2 infection hospitalization and mortality rates in pregnant patients in Washington State compared with the 20- to 39-year-old general population. The RD indicates the absolute RD associated with SARS-CoV-2 infections in pregnant patients in Washington State compared with the 20- to 39-year-old adults.

CI, confidence interval; COVID-19, coronavirus disease 2019; RD, rate difference; RR, rate ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WA-CPC, Washington State COVID-19 in Pregnancy Collaborative.

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

SARS-CoV-2 deaths among 20- to 39-year-olds in Washington State. In addition, the case-fatality rate in pregnant and recently pregnant patients with SARS-CoV-2 infections of 1250 of 100,000 pregnancies is in stark contrast to the Washington State maternal mortality rate of 37.3 of 100,000 live births and pregnancy-related maternal mortality rate of 11.2 of 100,000 live births.<sup>21</sup> Nearly half of the hospitalized patients delivered during a hospital admission for respiratory concerns, which raises the risk of preterm birth and associated complications of prematurity.<sup>22</sup> Notably, these deaths occurred after the “first wave” in Washington State and at a time when remdesivir and other therapeutics (dexamethasone) were administered to many patients in our study. The case-fatality rate and morbidity associated with SARS-CoV-2 infections in pregnancy in Washington States provide additional evidence for enhanced COVID-19 disease in pregnancy.

### Results in the context of what is known

The CDC listed pregnant patients as a population at an increased risk of severe

COVID-19 disease only recently after an expanded analysis of United States surveillance data of reproductive-aged women with SARS-CoV-2 infections.<sup>9,12,23</sup> Pregnant patients with SARS-CoV-2 were at an increased risk of ICU admission, ventilation, and death; however, pregnancy status was missing for 64.5% of COVID-19 cases.<sup>12</sup> Notably, in mid-October of 2020, the CDC reported only 45 maternal deaths in pregnant women with confirmed SARS-CoV-2 infections across the United States<sup>9</sup>; if complete, this would mean that the 3 cases in our study population represented 7% of the total maternal deaths in pregnant women with SARS-CoV-2 across the United States despite annual births among our study sites making up an estimated 1.4% of the total nationwide.<sup>24</sup> This is most likely caused by underreporting and not a higher death rate in Washington State. There is a long history of underreporting pregnancy status in important surveillance data including infectious disease reporting and in United States death records<sup>25</sup>; although efforts are ongoing to rectify this, we are concerned that pregnant patients are at an increased risk

of maternal mortality owing to COVID-19 and that deaths in this unique group may be significantly undercounted in the United States.

Our finding that deaths in pregnant patients contributed disproportionately to deaths from COVID-19 among 20- to 39-year-olds in Washington State is similar to what was observed during the influenza A virus (IAV) H1N1 2009 pandemic. Although approximately 1% of the United States population is pregnant at any point in time, deaths in pregnant women contributed 5.7% of all deaths from IAV H1N1 2009 in pooled data from a systematic review.<sup>26</sup> Similar to deaths in pregnant patients from IAV H1N1 2009, all 3 pregnant patients with a SARS-CoV-2 infection in our study who died were obese or had other underlying conditions.<sup>14,27,28</sup> Notably, 2 of 3 maternal deaths occurred after delivery after a prolonged or second hospitalization for COVID-19—associated complications highlighting the postpartum period as a high-risk period; this was also a high-risk time period for maternal mortality owing to IAV H1N1 2009.<sup>29</sup> However, unlike the IAV H1N1 2009 pandemic when pregnant women were

TABLE 5

## Maternal, delivery, and neonatal outcomes among pregnant patients with SARS-CoV-2 infections overall and by trimester of infection

Characteristics <sup>a</sup>	Overall <sup>b</sup>	Trimester of infection		P value
		Second	Third	
Pregnancy outcome	n=155	n=27	n=128	
Live birth	153 (98.7)	26 (96.3)	127 (99.2)	
Stillbirth	2 (1.3)	1 (3.7)	1 (0.8)	
Delivery characteristics	n=155	n=27	n=128	
Timing				
Time from the first COVID-19 positive test to outcome (d)	20 (2–58)	99 (85–105)	8 (1–35)	.0001
Gestational age at delivery (wk)	39.1 (38.1–40)	38.4 (37.6–39.1)	39.1 (38.4–40)	.02
Preterm birth	15 (9.7)	4 (14.8)	11 (8.6)	.32
Owing to preterm labor or PPRM	7 (46.7)	3 (75.0)	4 (36.4)	.19
Mode of delivery				
Induction (n=121 with any labor)	49 (40.5)	9 (39.1)	40 (40.8)	.88
Cesarean delivery	55 (35.5)	9 (33.3)	46 (35.9)	.80
Delivery induced or performed owing to COVID-19 <sup>c</sup>	9 (5.8)	0 (0)	9 (7.0)	.16
Obstetrical and fetal complications	n=155	n=27	n=128	
Gestational diabetes	16 (10.3)	2 (7.4)	14 (10.9)	.58
New-onset hypertensive disorder of pregnancy or postpartum <sup>d</sup>	19 (12.3)	3 (11.1)	16 (12.3)	.84
Diagnosed at or after COVID-19 diagnosis	17 (89.5)	3 (100)	14 (87.5)	.52
Nonreassuring fetal status/fetal distress	19 (12.3)	3 (11.1)	16 (12.5)	.84
Neonatal outcomes	n=156 <sup>e</sup>	n=26	n=130	
Birthweight (g) <sup>f</sup>	3261 (2905, 3640)	3206 (2887–3510)	3261 (2908, 3665)	.38
Low birthweight (<2500 g)	7 (4.6)	0 (0)	7 (5.5)	.22
SARS-CoV-2 testing performed <sup>g</sup>	45 (31.3)	1 (4.2)	44 (36.7)	.002
SARS-CoV-2 positive	0 (0)	—	—	
NICU admission <sup>h</sup>	11 (7.1)	1 (3.9)	10 (7.8)	.48

COVID-19, coronavirus disease 2019; HELLP, hemolysis, elevated liver enzymes, and a low platelet count; IQR, interquartile range; NICU, neonatal intensive care unit; PPRM, preterm premature rupture of membranes; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Presented as n (percentage) and median (IQR); <sup>b</sup> Excludes 3 cases of SARS-CoV-2 infection during the first trimester; 2 cases ended in spontaneous abortion and 1 led to a maternal death; <sup>c</sup> COVID-19 was either the singular indication or a contributory indication for delivery; <sup>d</sup> A new-onset hypertensive disorder of pregnancy or postpartum included any of the following diagnoses: new-onset gestational hypertension, preeclampsia, eclampsia, chronic hypertension with superimposed preeclampsia, and HELLP; <sup>e</sup> Live births only (n=156). There were 3 twin gestations; <sup>f</sup> Birthweight is missing for 2 neonates (n=154); <sup>g</sup> Testing data missing for 12 neonates, for a total of 24 neonates born to pregnant patients with second-trimester SARS-CoV-2 infections and 120 neonates born to pregnant patients with third-trimester SARS-CoV-2 infections; <sup>h</sup> NICU admission occurred for a neonatal health indication. Does not include NICU admission solely for COVID-19 precautions. N=155, data missing for 1 neonate.

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

quickly identified in the United States as a high-risk and vulnerable group,<sup>30,31</sup> pregnancy was not identified as a high-risk condition for COVID-19 disease or mortality for the first critical 8 months of the pandemic. Given the similarity in clinical course between COVID-19 and IAV H1N1 2009 with an increased risk of

mortality during pregnancy and the postpartum period, we strongly recommend that pregnant patients should be considered a high-risk population to novel highly pathogenic respiratory viruses until proven otherwise by population-based studies with good ascertainment of pregnancy status.

### Research implications

The impact of COVID-19 on maternal and neonatal health is limited by the paucity of data sets that capture outcomes from hospitalized and nonhospitalized cases across all trimesters of pregnancy. In our study in Washington State, pregnant patients with severe or

TABLE 6

**Maternal, delivery, and neonatal outcomes among pregnant patients with SARS-CoV-2 infections by infection status at delivery**

Characteristics <sup>a</sup>	COVID-19 status at delivery			P value
	Recovered at delivery n=67	Mild COVID-19 at delivery n=77	Severe or critical COVID-19 at delivery <sup>b</sup> n=11	
Delivery characteristics <sup>c</sup>				
Timing				
Time from first COVID-19 positive test to outcome (d)	58 (34,092)	3 (0–11)	8 (3–14)	.0001
Gestational age at delivery (wk)	39 (37.7–40)	39.3 (38.6–40.1)	37 (33.9–39.1)	<.01
Preterm birth	6 (9.0)	4 (5.2)	5 (45.4)	<.001
Owing to preterm labor or PPRM	5 (83.3)	1 (25.0)	1 (20.0)	.07
Mode of delivery				
Induction (n=121 with any labor)	23 (39.7)	24 (41.4)	2 (40.0)	.98
Cesarean delivery	22 (32.8)	26 (33.8)	7 (63.6)	.13
Delivery induced or performed owing to COVID-19 <sup>d</sup>	0 (0)	2 (2.6)	7 (63.6)	<.001
Obstetrical or fetal complications	n=67	n=77	n=11	
Gestational diabetes	8 (11.9)	6 (7.8)	2 (18.2)	.48
New-onset hypertensive disorder of pregnancy or postpartum <sup>e</sup>	5 (7.5)	14 (18.2)	0 (0)	.07
Diagnosed at or after COVID-19 diagnosis	5 (100.0)	12 (85.7)	0 (0)	.37
Nonreassuring fetal status or fetal distress	4 (6.0)	9 (11.7)	6 (54.6)	<.001
Neonatal outcomes <sup>f</sup>	n=67	n=78	n=11	
Birthweight (g) <sup>g</sup>	3261 (2950–3560)	3304 (2955, 3705)	2690 (2490–3020)	<.001
Low birthweight (<2500 g)	2 (3.0)	2 (2.6)	3 (27.3)	.001
SARS-CoV-2 testing performed <sup>h</sup>	3 (5.3)	35 (44.9)	7 (77.9)	<.001
NICU admission <sup>i</sup>	2 (3.0)	6 (7.7)	3 (27.3)	.01

COVID-19, coronavirus disease 2019; HELLP, hemolysis, elevated liver enzymes, and a low platelet count; IQR, interquartile range; NICU, neonatal intensive care unit; PPRM, preterm premature rupture of membranes; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Presented as number (percentage) and median(IQR); <sup>b</sup> One patient was readmitted several months after a severe COVID-19 infection owing to a COVID-19–associated complication and was considered to have “active COVID-19” in this analysis although she had a negative polymerase chain reaction test result at the time; <sup>c</sup> n=155, excluding 2 spontaneous abortions; <sup>d</sup> COVID-19 was the singular indication or a contributing indication for delivery; <sup>e</sup> Data collection tools included new-onset gestational hypertension, preeclampsia, eclampsia, chronic hypertension with superimposed preeclampsia, and HELLP; <sup>f</sup> Live births only (n=156). There were 3 twin gestations; <sup>g</sup> Birthweight is missing for 2 neonates (n=154); <sup>h</sup> Testing data missing for 12 neonates, for a total of 57 neonates born to pregnant patients considered COVID-19 recovered at delivery, 78 neonates born to pregnant patients with mild COVID-19 at delivery, and 9 neonates born to pregnant patients with severe COVID-19 at delivery; <sup>i</sup> NICU admission occurred for a neonatal health indication. Does not include NICU admission solely for COVID-19 precautions. n=155, data missing for 1 neonate.

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

critical disease at the time of delivery had a higher likelihood of preterm birth, which can have important long-term adverse impacts on the lifelong health of the child (eg, brain and lung injury).<sup>32,33</sup> When comparing outcomes by trimester of SARS-CoV-2 infection, pregnancy complications and delivery outcomes were similar; however, the number of delivery outcomes for second-trimester infections was small so this finding does not prove an absence of

differential outcomes by trimester of infection. Further studies of pregnancy outcomes by trimester of infection will be important to determine whether there is an impact of pregnancy complications, fetal growth, and neonatal outcomes. Finally, it will be important to follow neonates for many years to determine the long-term sequelae of the spectrum of maternal COVID-19 disease; in particular, the risk of neuropsychiatric disease, such as autism spectrum

disorder, is important to determine after a several maternal infection.<sup>34,35</sup>

### Strengths and limitations

This study's major strength was its capture of confirmed SARS-CoV-2 cases from 35 sites across Washington State representing 61% of annual deliveries across the state. Including cases from all trimesters of pregnancy and regardless of symptoms status enabled a more thorough examination of spectrum of SARS-

CoV-2 infection in pregnancy. In addition, we ascertained the reason for hospitalization; distinguished among hospitalizations that were for COVID-19 disease, delivery, or another indication; and assessed outcomes by whether the pregnant patient had active COVID-19 at the time of delivery vs earlier in pregnancy. This study also had limitations, including the potential for underascertainment of asymptomatic and milder cases, particularly earlier in pregnancy, despite several methods for case detection across sites. Therefore, the severity of cases and our hospitalization and maternal mortality estimates may be an under- or overestimate of the state-wide rates. Moreover, data collection was completed before pregnancy outcome data for first-trimester and most second-trimester pregnancies would have occurred limiting the inference we are able to make about the trimester of infection and adverse maternal and neonatal outcomes. Finally, the SARS-CoV-2 case-fatality point estimates in pregnant patients and the relative comparisons to crude COVID-19 case-fatality rates among similarly aged Washingtonians should be cautiously interpreted given the rare outcomes under study, potential for selection bias, and use of imperfect denominators for comparison owing to limitations in publicly available data (eg, all 20- to 39-year-old females and males in Washington State). The ideal state-wide comparison group would have been nonpregnant reproductive-aged women with SARS-CoV-2 infections which is not currently publicly available. Nevertheless, this study provides further evidence that pregnant patients with COVID-19 are at an elevated risk of poor maternal outcomes and should be targeted for pregnancy and infant outcome surveillance.

## Conclusions

Our finding of a markedly higher mortality rate among pregnant people with SARS-CoV-2 infection in a state-wide multicenter cohort study representing the majority of annual births in Washington State is compelling evidence that pregnant patients are a population at high

risk of morbidity and mortality associated with SARS-CoV-2 infection. The overall 1 in 80 maternal mortality rate in pregnancy coupled with the potential overrepresentation of pregnant people in Washington State's SARS-CoV-2 deaths in 20- to 39-year-olds is cause for concern. Furthermore, these maternal deaths represented 7% of those known to the CDC in mid-October despite our population representing only 1.4% of the nation's births; this suggests undercounting of maternal deaths, which is likely given the missing pregnancy status in 65% of COVID-19 case reports.<sup>12</sup> We also found a significantly higher likelihood of preterm birth in pregnant patients with severe or critical COVID-19 disease is concerning given the long-term adverse outcomes on a child's health through the life course.<sup>10,11,36</sup> Greater attention to pregnant patients as a unique population at higher risk of SARS-CoV-2 infection sequelae is critical to preventing maternal and neonatal morbidity and mortality. These data strongly support the need to offer vaccination to pregnant women at risk of acquiring SARS-CoV-2 infection and include pregnant people in clinical trials and other observational evaluations of vaccines and COVID-19 therapies (Video 1).<sup>37–42</sup> ■

## Acknowledgments

We thank the pregnant patients contributing data to this article and our partners across Washington State that enabled this investigation. We also recognize the differences between sex and gender, noting that the term "women" is not inclusive for biologically born female individuals that identify as nonbinary or transgender. We thank Jane Edelson, who provided assistance with project management at the University of Washington. Adrienne Meyer with the University of Washington Human Subjects Division provided critical assistance to obtain reliance agreements with community institutional review boards. Barbara James graciously provided COVID-19 case counts for PeaceHealth Southwest. We thank Dr Robert Weston and Erin Andreas for reporting COVID-19 cases at Mid-Valley Hospital. Dr Peter Napolitano provided assistance with patient identification. We are grateful to Nicole Wothe for administrative assistance with this manuscript.

## References

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of

coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324:782–93.

2. Lokken EM, Walker CL, Delaney S, et al. Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State. *Am J Obstet Gynecol* 2020;223:911.e1–14.

3. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ* 2020;369:m2107.

4. Savasi VM, Parisi F, Patané L, et al. Clinical findings and disease severity in hospitalized pregnant women with coronavirus disease 2019 (COVID-19). *Obstet Gynecol* 2020;136:252–8.

5. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19. *Am J Obstet Gynecol* 2020;223:109.e1–16.

6. Hirshberg A, Kern-Goldberger AR, Levine LD, et al. Care of critically ill pregnant patients with coronavirus disease 2019: a case series. *Am J Obstet Gynecol* 2020;223:286–90.

7. Panagiotakopoulos L, Myers TR, Gee J, et al. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. Health care centers, March 1-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1355–9.

8. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–75.

9. Centers for Disease Control and Prevention. Data on COVID-19 during pregnancy: severity of maternal illness. 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19.html>. Accessed Feb. 7, 2021.

10. Woodworth KR, O'Malley Olsen E, Neelam V, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 Jurisdictions, March 29–October 14, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1635–40.

11. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. *Am J Obstet Gynecol MFM* 2020;2:100134.

12. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1641–7.

13. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, UKOSS. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. *BMJ* 2011;342:d3214.

14. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. *Obstet Gynecol* 2010;115:717–26.

15. Centers for Disease Control and Prevention (CDC). 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. *MMWR Morb Mortal Wkly Rep* 2010;59:321-6.
16. Washington State Department of Health. Birth certificate data, 2000-2018, community health assessment tool (CHAT). 2019. Available at: <https://www.doh.wa.gov/DataandStatisticalReports/HealthDataVisualization/BirthDashboards/AIBirthsACH>. Accessed Aug. 21, 2020.
17. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239-42.
18. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol* 2020;2:100118.
19. Washington State Department of Health. COVID-19 in Washington State: confirmed cases, hospitalizations and deaths by week of illness onset, county, and age. 2020. Available at: <https://www.doh.wa.gov/Emergencies/COVID19/DataDashboard>. Accessed Oct. 20, 2020.
20. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. *Obstet Gynecol* 2009;114:1326-31.
21. Washington State Department of Health. Maternal Mortality Review Panel: maternal deaths 2014-2016 2019. Available at: <https://www.doh.wa.gov/Portals/1/Documents/Pubs/141-010-MMRPMaternalDeathReport2014-2016.pdf>. Accessed Feb. 8, 2021.
22. Blencowe H, Cousens S, Chou D, et al. Born too soon: the global epidemiology of 15 million preterm births. *Reprod Health* 2013;10(Suppl1):S2.
23. Centers for Disease Control and Prevention. People with certain medical conditions. 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>. Accessed Feb. 7, 2021.
24. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2018. *Natl Vital Stat Rep* 2019;68:1-47.
25. Hoyert DL, Uddin SFG, Miniño AM. Evaluation of the pregnancy status checkbox on the identification of maternal deaths. *Natl Vital Stat Rep* 2020;69:1-25.
26. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 Pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. *Am J Obstet Gynecol* 2011;205:10-8.
27. Louie JK, Acosta M, Jamieson DJ, Honein MA. California Pandemic (H1N1) Working G. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. *N Engl J Med* 2010;362:27-35.
28. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. *JAMA* 2010;303:1517-25.
29. Centers for Disease Control and Prevention (CDC). Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)—United States, April 2009–August 2010. *MMWR Morb Mortal Wkly Rep* 2011;60:1193-6.
30. Centers for Disease Control and Prevention (CDC). Novel influenza A (H1N1) virus infections in three pregnant women—United States, April–May 2009. *MMWR Morb Mortal Wkly Rep* 2009;58:497-500.
31. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet* 2009;374:451-8.
32. Raju TNK, Pemberton VL, Saigal S, et al. Long-term healthcare outcomes of preterm birth: an executive summary of a conference sponsored by the National Institutes of Health. *J Pediatr* 2017;181:309-18.e1.
33. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. *N Engl J Med* 2008;359:262-73.
34. Al-Haddad BJS, Jacobsson B, Chabra S, et al. Long-term risk of neuropsychiatric disease After exposure to infection in utero. *JAMA Psychiatry* 2019;76:594-602.
35. Al-Haddad BJS, Oler E, Armistead B, et al. The fetal origins of mental illness. *Am J Obstet Gynecol* 2019;221:549-62.
36. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet* 2008;371:261-9.
37. LaCourse SM, John-Stewart G, Adams Waldorf KM. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials. *Clin Infect Dis* 2020;71:879-81.
38. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. *Case Rep Womens Health* 2020;27:e00221.
39. Burwick RM, Yawetz S, Stephenson KE, et al. Compassionate use of remdesivir in pregnant women with severe Covid-19. *Clin Infect Dis* 2020 [Epub ahead of print].
40. Craig AM, Hughes BL, Swamy GK. COVID-19 vaccines in pregnancy. *Am J Obstet Gynecol* 2020 [Epub ahead of print].
41. Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine (SMFM) statement: SARS-CoV-2 vaccination in pregnancy. 2020. Available at: [https://s3.amazonaws.com/cdn.smfm.org/media/2591/SMFM\\_Vaccine\\_Statement\\_12-1-20\\_\(final\).pdf](https://s3.amazonaws.com/cdn.smfm.org/media/2591/SMFM_Vaccine_Statement_12-1-20_(final).pdf). Accessed Feb. 7, 2021.
42. The American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19. 2020. Available at: <https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-Pregnant-and-Lactating-Patients-Against-COVID-19>. Accessed Feb. 7, 2021.

### Author and article information

From the Department of Global Health (Drs Lokken, LaCourse, and Waldorf), Department of Obstetrics and Gynecology (Drs Lokken, Kachikis, McCartney, Kretzer, Ma, Albright, Hsu, A. Erickson, Hwang, Delaney, and Waldorf), Department of Epidemiology (Ms Taylor), Department of Pediatrics (Dr al-Haddad), and Department of Medicine (Dr LaCourse), University of Washington, Seattle, WA; University of Washington School of Medicine, Seattle, WA (Ms Huebner, Dr Resnick, Ms Schulte, Ms Bergam, Ms Rah, and Dr S. Erickson); Yakima Valley Farm Workers Clinic, Yakima, WA (Dr Hendrickson, Mss Valerie Larios, Kelley, and Victoria Larios, and Mr Chang); Swedish Maternal and Fetal Specialty Center—First Hill, Seattle, WA (Dr Vanderhoeven); Obstetrix Medical Group of Washington, Seattle, WA (Dr Vanderhoeven); Elson S. Floyd College of Medicine, Washington State University, Spokane, WA (Mr Coler and Dr S. Erickson); MultiCare Health System, Tacoma, WA (Dr Walker); MultiCare Regional Maternal-Fetal Medicine, Tacoma, WA (Dr Sheng); Department of Obstetrics and Gynecology, PeaceHealth St. Joseph Medical Center, Bellingham, WA (Drs Barnhart and Thomas); Virginia Mason Memorial, Yakima, WA (Ms Emhoff); Quality Department (Ms Retzlaff) and Eastside Maternal-Fetal Medicine (Drs Paek and Kline), EvergreenHealth Medical Center Kirkland, Kirkland, WA; Obstetrix Medical Group of Washington, Bellevue, WA (Drs Paek and Kline); Women's and Children's Health, Confluence Health, Wenatchee, WA (Dr Hsu); Department of Obstetrics and Gynecology, Vancouver Clinic, Vancouver, WA (Dr Mitchell); Jefferson Healthcare, Port Townsend, WA (Dr S. Erickson); and Legacy Medical Group—Maternal-Fetal Medicine, Legacy Health, Vancouver, WA (Dr Archabald).

Received Nov. 10, 2020; revised Dec. 20, 2020; accepted Dec. 30, 2020.

Ms Huebner and Ms Taylor contributed equally to this work.

A.K. is on a Pfizer Inc and GlaxoSmithKline plc Advisory Board for Immunization, which is unrelated to the content of this article.

This work was supported primarily by funding from the Department of Obstetrics and Gynecology, University of Washington Population Health Initiative, and philanthropic gift funds. This work was also supported by the National Institute of Allergy and Infectious Diseases (grant numbers AI133976, AI145890, AI143265, and HD098713 to K.A.W., HD001264 to A.K. and AI120793 to S.M.L.) and by the National Institute of General Medical Sciences (T32 GM008244 for B.J.S.A.). Study data were managed using a Research Electronic Data Capture electronic data capture tool hosted by the Institute of Translational Health Sciences at the University of Washington, which was supported by the National Center for Advancing Translational Sciences (UL1TR002319). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the National Institutes of Health or other funders.

Corresponding author: Kristina M. Adams Waldorf, MD. [adamsk@uw.edu](mailto:adamsk@uw.edu)

**SUPPLEMENTAL TABLE**  
**WA-CPC participating sites**

	Participating site	Type	Annual delivery volume <sup>a</sup>
1	University of Washington Medical Center: Montlake	Hospital	1900
2	University of Washington Medical Center: Northwest	Hospital	900
3	Swedish: Issaquah	Hospital	12,000 system-wide <sup>b</sup>
4	Swedish: First Hill	Hospital	<sup>b</sup>
5	Swedish: Ballard	Hospital	<sup>b</sup>
6	Swedish: Edmonds	Hospital	<sup>b</sup>
7	University of Washington Valley Medical Center	Hospital	3200
8	MultiCare: Covington Medical Center	Hospital	250
9	MultiCare: Auburn Medical Center	Hospital	1108
10	MultiCare: Tacoma General Hospital	Hospital	2921
11	MultiCare: Good Samaritan Hospital	Hospital	2227
12	MultiCare: Spokane Valley Hospital	Hospital	604
13	MultiCare: Deaconess Medical Center	Hospital	1384
14	EvergreenHealth Medical Center - Kirkland	Hospital	4600
15	PeaceHealth St. Joseph Medical Center—Bellingham	Hospital	1875
16	Providence Regional Medical Center—Everett	Hospital	4250
17	Jefferson Medical Center	Hospital	125
18	Legacy Salmon Creek Medical Center	Hospital	3600
19	Virginia Mason Memorial Hospital	Hospital	2385
20	Central WA Hospital, Confluence	Hospital	1300
21	UW Medicine Maternal-Fetal Medicine Clinic at Yakima	Clinic <sup>c</sup>	n/a
22	Yakima Valley Farm Workers Clinics: Valley Vista Medical Group	Clinic	119
23	Yakima Valley Farm Workers Clinics: Pasco Miramar Health Center	Clinic	6
24	Yakima Valley Farm Workers Clinics: Unify Community Health, Mission Avenue	Clinic	134
25	Yakima Valley Farm Workers Clinics: Unify Community Health, West Central Community Center	Clinic	48
26	Yakima Valley Farm Workers Clinics: Unify Community Health, Northeast Community Center	Clinic	122
27	Yakima Valley Farm Workers Clinics: Grandview Medical Dental Clinic	Clinic	356
28	Yakima Valley Farm Workers Clinics: Lincoln Avenue Medical Dental	Clinic	1809
29	Yakima Valley Farm Workers Clinics: Yakima Medical Dental Clinic	Clinic	1356
30	Yakima Valley Farm Workers Clinics: Mountain View Women's Clinic	Clinic	242
31	Yakima Valley Farm Workers Clinics: Toppenish Medical Dental Clinic	Clinic	1164
32	Yakima Valley Farm Workers Clinics: Family Medical Center Walla Walla	Clinic	283

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.

(continued)

## SUPPLEMENTAL TABLE

## WA-CPC participating sites (continued)

	Participating site	Type	Annual delivery volume <sup>a</sup>
33	The Vancouver Clinic	Clinic <sup>d</sup>	n/a <sup>d</sup>
34	PeaceHealth Southwest Medical Center	Hospital	2000
35	Mid Valley Hospital	Hospital	240

<sup>a</sup> Collaborating sites reported their approximate annual delivery number. The annual delivery numbers for MultiCare facilities are the 2019 actuals. The annual delivery numbers for the Yakima Valley Farm Workers Clinics are the number of women in their care who delivered in 2019; <sup>b</sup> Annual delivery volume is reported system-wide for Swedish Medical Center sites; <sup>c</sup> Deliveries occur across Greater Yakima region; <sup>d</sup> Vancouver Clinic patients deliver at PeaceHealth Southwest Medical Center and Legacy Salmon Creek Medical Center. The total number of deliveries at the Vancouver Clinic do not count toward total number of annual deliveries captured by the Washington State COVID-19 in Pregnancy Collaborative because they are included with PeaceHealth Southwest Medical Center and Legacy Salmon Creek Medical Center numbers.

Lokken et al. COVID-19 disease and mortality in pregnancy. *Am J Obstet Gynecol* 2021.